Original reporting and analysis on the stories shaping biotech.
A federal judge blocked Colorado's first-ever state price cap on Amgen's Enbrel, ruling that capping the price of a patented drug likely violates federal law. The decision could freeze similar efforts in a dozen other states.
Anthropic launched Claude Science, an AI research workbench that connects to 60+ scientific databases and promises to compress years of pharma R&D into days. But there's a catch: the company also wants to discover its own drugs, putting it in direct competition with the customers it's courting.
Roche launched its AXELIOS 1 gene sequencer, pricing genomes at $150 and taking direct aim at Illumina's decade-long grip on the sequencing market. With 13 years of failed attempts behind it, Roche's comeback is backed by new chemistry, heavyweight partnerships, and pricing that could reshape genomic medicine.
Two Nature papers unveil a CAR-T therapy that kills solid tumors and the immune cells protecting them, with the first human patient showing six months of disease control and zero serious side effects. GPNMB might be the solid-tumor target the field has been searching for.
Valneva pulled the world's only chikungunya vaccine from the U.S. after FDA suspension, safety deaths, and dismal sales. With the disease surging globally, the withdrawal exposes a painful truth about tropical disease vaccines and the market's refusal to support them.
Sandoz just got FDA acceptance for generic versions of Eli Lilly's blockbuster weight-loss drug tirzepatide, setting up a long-game challenge to the $100 billion GLP-1 market. Patents keep the launch years away, but the world's biggest generics maker is already plotting price cuts that could reshape who gets access to obesity treatment.
Zymeworks, an oncology biotech known for its HER2-targeting cancer drugs, just dropped $929 million to buy a COPD lung treatment. The financing structure is clever, the strategic logic is surprisingly sound, and the real test comes in August.
For six years, Tepezza was the only FDA-approved drug for thyroid eye disease, generating nearly $2 billion in annual sales with zero competition. Viridian Therapeutics just changed that with the approval of Lumvoa, and the monopoly's days are officially numbered.
A drug that flopped in lupus and MS just posted blockbuster kidney disease data, and the FDA decision is days away. Atacicept's unlikely redemption arc could reshape the IgA nephropathy market.
The FDA is about to let a panel of peptide-selling doctors and pharmacists vote on whether their own products should be legal. Critics say the July advisory committee meeting is a case study in regulatory capture, with billions in gray-market sales hanging in the balance.
Roche's divarasib just outperformed both approved KRAS G12C inhibitors in a head-to-head Phase 3 trial, hitting superiority on both progression-free survival and overall survival. Wall Street says it's a solid win, but the real billions hinge on what comes next.
Sensorion just reported the first human data from its gene therapy trial in deaf toddlers, and children who previously heard nothing are starting to respond to sound. The results are early, but they could reshape how we treat one of the most common genetic causes of childhood deafness.
MacroGenics just sold its entire manufacturing operation to Bora Pharmaceuticals for $122.5 million, bucking the industry's vertical integration trend. It's a bold bet that a clinical-stage biotech is better off renting a factory than owning one.
United Therapeutics dropped $140 million on a startup that wants to regrow your thymus, the immune organ most people forgot they had. It sounds wild until you realize it might be the missing piece for the company's even wilder plan to manufacture unlimited transplant organs.
Forty private biotech companies raised $100M+ in the first half of 2026, and the largest biotech IPO ever just closed at $625M. But the money is piling into a handful of winners while early-stage companies face their worst funding year in a decade. Welcome to biotech's K-shaped boom.
Ipsen dropped $2.5 billion on two biotech acquisitions in five days, including a Swiss startup targeting a virus that threatens kidney transplants. The science behind the deal is as compelling as the price tag.
Sixth Street and KKR just injected $1 billion of preferred equity into BridgeBio Pharma, one of the largest such deals ever for a public biotech. The unusual structure reveals a new financing playbook for late-stage drug companies caught between clinical success and commercial scale.
Merck killed its Phase 2 trial of MK-1167 after the Alzheimer's drug simply didn't work well enough. With a 99.6% failure rate in the field and only one remaining candidate in their pipeline, Merck's neuroscience ambitions are running out of runway.
Takeda is paying Insilico Medicine up to $600 million to let an AI platform design its next wave of drug candidates. It's the latest mega-deal in a pharma-wide arms race for generative AI, and Insilico's growing roster of blue-chip partners is starting to look like a who's-who of big pharma.
The FDA just approved Orca Bio's Tregzi, the first regulatory T cell therapy designed to make bone marrow transplants dramatically safer. In its pivotal trial, 78% of patients survived without serious GVHD at one year, versus just 38% with standard transplants. This one's worth understanding.
For nearly 50 years, carbapenems were the most powerful antibiotics in medicine, but they required an IV and a hospital bed. GSK just changed that with the first-ever oral carbapenem, and the implications for millions of UTI patients (and antibiotic resistance) are enormous.
Medicare's new GLP-1 Bridge pilot offers weight-loss drugs like Wegovy and Zepbound to seniors for just $50 a month, blowing past decades of coverage bans. It's a multibillion-dollar bet that treating obesity now will save money later, and Wall Street is already picking winners.
Join thousands of biotech professionals who start their day with our free, daily briefing.